Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.54 USD
Change Today -0.0217 / -3.85%
Volume 707.5K
KBIO On Other Exchanges
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

kalobios pharmaceuticals inc (KBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/14 - $2.66
52 Week Low
02/4/15 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

kalobios pharmaceuticals inc (KBIO) Related Businessweek News

No Related Businessweek News Found

kalobios pharmaceuticals inc (KBIO) Details

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.

32 Employees
Last Reported Date: 03/16/15
Founded in 2000

kalobios pharmaceuticals inc (KBIO) Top Compensated Officers

Chief Scientific Officer
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.

kalobios pharmaceuticals inc (KBIO) Key Developments

KaloBios Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM

KaloBios Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Herbert C. Cross, Interim Chief Executive Officer and Chief Financial Officer.

Kalobios Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

KaloBios Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported contract revenue of $44,000 a year ago. Loss from operations was $36,718,000 compared to $40,909,000 a year ago. Net loss was $37,998,000 or $1.15 basic and diluted per share compared to $41,948,000 or $1.73 basic and diluted per share a year ago.

KaloBios Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

KaloBios Pharmaceuticals, Inc. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KBIO:US $0.54 USD -0.0217

KBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation KBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALOBIOS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at